Expert review of neurotherapeuticsHumansAlzheimer DiseaseParkinson DiseaseClinical Trials as TopicOutcome Assessment
Speech and language outcome measures in clinical trials of Alzheimer's and Parkinson's diseases.
Marcelo L Berthier, Alejandro Sosa-Welford, Juan Rafael Orozco-Arroyave, Diana López-Barroso, María José Torres-Prioris, Guadalupe Dávila, Adolfo M García
Published: 202610.1080/14737175.2025.2600616
Abstract
INTRODUCTION: Alongside core diagnostic symptoms, Alzheimer's disease (AD) and Parkinson's disease (PD) involve early and pervasive speech-language impairments (SLI), often appearing in preclinical stages and capturing disease severity. However, spee…
Preview only. Read the full abstract at the source